Jakarta, Indonesia Sentinel — Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) is aiming to secure a vaccine export contract worth IDR 3 trillion ($190 million) by next year.
Bio Farma’s Deputy CEO, Soleh Ayubi, revealed that the company has already secured an IDR 1.4 trillion ($88 million) contract following a major meeting of global pharmaceutical companies in São Paulo, Brazil, in October.
“We’ve been trusted to supply a range of vaccines, including polio, diphtheria, tetanus, and pertussis, with a total contract value of about 1.4 trillion rupiah for 2025 alone. We expect this to continue expanding,” Soleh explained during a press conference at the Indonesian State-Owned Enterprises Ministry on November 1, 2024.
Bio Farma, which supplies vaccines to 153 countries, has an extensive product lineup. According to Soleh, the company’s production hub in Pasteur, Bandung, plays a crucial role in meeting global demand.
“Any disruptions in our Bandung plant impact 150 countries. Delays at that one point cause a ripple effect worldwide,” he emphasized.
The Pasteur facility currently has an annual production capacity of 3.1 billion vaccine doses, with plans to expand output fivefold to bolster revenue. Bio Farma is also exploring a tenfold increase in capacity. To meet growing demand, the company is considering three potential sites for a new manufacturing plant, though site selection depends on environmental assessments, particularly water availability.
Agriculture Ministry Awaits BPOM Tests on Shine Muscat Grapes, Potential Ban Looms!
“Water is crucial. At Pasteur, we need five million liters annually just for vaccine production. Green energy options will also be critical in deciding our next steps,” Soleh noted.
This focus on sustainable resources underscores Bio Farma’s commitment to ensuring the reliability of its vaccine supply chain and expanding its international reach.
(Becky)
